These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 8751395)

  • 1. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma.
    Dattoli M; Wallner K; Sorace R; Koval J; Cash J; Acosta R; Brown C; Etheridge J; Binder M; Brunelle R; Kirwan N; Sanchez S; Stein D; Wasserman S
    Int J Radiat Oncol Biol Phys; 1996 Jul; 35(5):875-9. PubMed ID: 8751395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of serum prostatic acid phosphatase for 103Pd-based radiation for prostatic carcinoma.
    Dattoli M; Wallner K; True L; Sorace R; Koval J; Cash J; Acosta R; Biswas M; Binder M; Sullivan B; Lastarria E; Kirwan N; Stein D
    Int J Radiat Oncol Biol Phys; 1999 Nov; 45(4):853-6. PubMed ID: 10571189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
    Stock RG; Stone NN
    Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Urology; 2007 Feb; 69(2):334-7. PubMed ID: 17320673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.
    Merrick GS; Butler WM; Galbreath RW; Lief JH; Adamovich E
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):664-73. PubMed ID: 11849788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isotope selection for patients undergoing prostate brachytherapy.
    Cha CM; Potters L; Ashley R; Freeman K; Wang XH; Waldbaum R; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):391-5. PubMed ID: 10487561
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 20 Gy versus 44 Gy supplemental beam radiation with Pd-103 prostate brachytherapy: preliminary biochemical outcomes from a prospective randomized multi-center trial.
    Wallner K; Merrick G; True L; Sherertz T; Sutlief S; Cavanagh W; Butler W
    Radiother Oncol; 2005 Jun; 75(3):307-10. PubMed ID: 16086912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: influence of prostatic acid phosphatase.
    Dattoli M; Wallner K; True L; Cash J; Sorace R
    Cancer; 2003 Feb; 97(4):979-83. PubMed ID: 12569596
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 125I versus 103Pd for low-risk prostate cancer: preliminary PSA outcomes from a prospective randomized multicenter trial.
    Wallner K; Merrick G; True L; Sutlief S; Cavanagh W; Butler W
    Int J Radiat Oncol Biol Phys; 2003 Dec; 57(5):1297-303. PubMed ID: 14630265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.
    Fang LC; Dattoli M; Taira A; True L; Sorace R; Wallner K
    Urology; 2008 Jan; 71(1):146-50. PubMed ID: 18242384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is supplemental external beam radiation therapy necessary for patients with higher risk prostate cancer treated with 103Pd? Results of two prospective randomized trials.
    Merrick GS; Wallner KE; Galbreath RW; Butler WM; Fiano R; Orio PF; Adamovich E
    Brachytherapy; 2015; 14(5):677-85. PubMed ID: 26051802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate specific antigen findings and biopsy results following interactive ultrasound guided transperineal brachytherapy for early stage prostate carcinoma.
    Stock RG; Stone NN; DeWyngaert JK; Lavagnini P; Unger PD
    Cancer; 1996 Jun; 77(11):2386-92. PubMed ID: 8635111
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.
    Brachman DG; Thomas T; Hilbe J; Beyer DC
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):111-7. PubMed ID: 10924979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate brachytherapy: treatment strategies.
    Stone NN; Stock RG
    J Urol; 1999 Aug; 162(2):421-6. PubMed ID: 10411050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urinary morbidity following ultrasound-guided transperineal prostate seed implantation.
    Gelblum DY; Potters L; Ashley R; Waldbaum R; Wang XH; Leibel S
    Int J Radiat Oncol Biol Phys; 1999 Aug; 45(1):59-67. PubMed ID: 10477007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer.
    Merrick GS; Butler WM; Galbreath RW; Lief JH
    Int J Radiat Oncol Biol Phys; 2001 Sep; 51(1):41-8. PubMed ID: 11516849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.
    Ko EC; Stone NN; Stock RG
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):600-7. PubMed ID: 21985944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
    Martinez AA; Kestin LL; Stromberg JS; Gonzalez JA; Wallace M; Gustafson GS; Edmundson GK; Spencer W; Vicini FA
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):343-52. PubMed ID: 10802358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 20 Gy versus 44 Gy of supplemental external beam radiotherapy with palladium-103 for patients with greater risk disease: results of a prospective randomized trial.
    Merrick GS; Wallner KE; Butler WM; Galbreath RW; Taira AV; Orio P; Adamovich E
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(3):e449-55. PubMed ID: 22196131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.